News und Analysen
DGAP-News: Just – Evotec Biologics and Alpine Immune Sciences expand partnership for commercial process development of ALPN-303
DGAP-News: Just – Evotec Biologics and Alpine Immune Sciences expand partnership for commercial process development of ALPN-303
DGAP-News: STRATEC REPORTS RESULTS FOR FIRST HALF OF 2022 AND CONFIRMS FINANCIAL GUIDANCE
DGAP-News: STRATEC REPORTS RESULTS FOR FIRST HALF OF 2022 AND CONFIRMS FINANCIAL GUIDANCE
Study Using NanoString’s GeoMx Digital Spatial Profiler Featured on the Cover of Nature Genetics
NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced a peer-reviewed paper published in Nature Genetics
Gerresheimer AG: Gerresheimer invests up to 94 million Dollar in US production facility
Gerresheimer AG: Gerresheimer invests up to 94 million Dollar in US production facility
DGAP-News: Carl Zeiss Meditec achieves further significant growth in revenue and order intake after nine months of 2021/22
DGAP-News: Carl Zeiss Meditec achieves further significant growth in revenue and order intake after nine months of 2021/22
DGAP-News: Evotec SE reports first half-year 2022 results on 11 August 2022
DGAP-News: Evotec SE reports first half-year 2022 results on 11 August 2022
DGAP-News: RHÖN-KLINIKUM AG closes first half of 2022 with increase in revenues
DGAP-News: RHÖN-KLINIKUM AG closes first half of 2022 with increase in revenues
DGAP-News: MorphoSys AG Reports Second Quarter and First Half 2022 Financial Results
DGAP-News: MorphoSys AG Reports Second Quarter and First Half 2022 Financial Results
DGAP-News: PAION LAUNCHES ERAVACYCLINE FOR THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS IN ADULTS IN GERMANY
DGAP-News: PAION LAUNCHES ERAVACYCLINE FOR THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS IN ADULTS IN GERMANY
DGAP-News: MorphoSys AG: Invitation to MorphoSys’ Second Quarter and First Half Year 2022 Results Conference Call on August 4 , 2022
DGAP-News: MorphoSys AG: Invitation to MorphoSys’ Second Quarter and First Half Year 2022 Results Conference Call on August 4 , 2022
DGAP-News: Biotest AG: Biotest increases EBITDA in first half-year by 52% to 8.8 million EUR
DGAP-News: Biotest AG: Biotest increases EBITDA in first half-year by 52% to 8.8 million EUR
DGAP-News: Drägerwerk AG & Co. KGaA: Dräger expects significant recovery in business development in the second half of 2022
DGAP-News: Drägerwerk AG & Co. KGaA: Dräger expects significant recovery in business development in the second half of 2022
DGAP-Adhoc: Fresenius SE & Co. KGaA: Significantly worsening headwinds at Fresenius Medical Care impact Group net income in FY/22; Fresenius SE & Co. KGaA Group guidance revised
DGAP-Adhoc: Fresenius SE & Co. KGaA: Significantly worsening headwinds at Fresenius Medical Care impact Group net income in FY/22; Fresenius SE & Co. KGaA Group guidance revised
DGAP-Adhoc: Fresenius Medical Care AG & Co. KGaA cuts outlook for FY 2022 due to increased headwinds from U.S. labor market situation and global inflation, and withdraws 2025 targets
DGAP-Adhoc: Fresenius Medical Care AG & Co. KGaA cuts outlook for FY 2022 due to increased headwinds from U.S. labor market situation and global inflation, and withdraws 2025 targets
Dexcom G6 Continuous Glucose Monitoring System Mobile App Now Available in Spanish
Dexcom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today announced the launch of the Dexcom G6 mobile app in Spanish
DGAP-Adhoc: QIAGEN N.V.: QIAGEN increases full-year 2022 outlook
DGAP-Adhoc: QIAGEN N.V.: QIAGEN increases full-year 2022 outlook
Waters Collaborates with Leading Researchers and Industry Partners to Advance the Science of Alternative Proteins
Waters Corporation (NYSE:WAT) announced it is providing both technology and expertise to help advance plant-based protein science in collaboration with researchers of the Plant Protein Innovation
DGAP-News: MorphoSys Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
DGAP-News: MorphoSys Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
DGAP-Adhoc: Ad hoc: MorphoSys AG Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
DGAP-Adhoc: Ad hoc: MorphoSys AG Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
DGAP-Adhoc: STRATEC REPORTS PRELIMINARY FIGURES FOR FIRST HALF OF 2022 AND CONFIRMS FINANCIAL GUIDANCE
DGAP-Adhoc: STRATEC REPORTS PRELIMINARY FIGURES FOR FIRST HALF OF 2022 AND CONFIRMS FINANCIAL GUIDANCE
DGAP-News: Biotest AG: Biotest grants Renate & Hans Schleussner Research Award for the first time
DGAP-News: Biotest AG: Biotest grants Renate & Hans Schleussner Research Award for the first time
CORRECTING and REPLACING Clovis Oncology to Announce Second Quarter 2022 Financial Results and Host Webcast Conference Call on August 8
First paragraph, second sentence of release should read: Clovis’ senior management will host a conference call and live audio webcast at 8:30am ET to discuss Clovis’ results and business outlook in
GenSight Biologics reports 5 years’ data showing sustained efficacy and safety following one-time treatment with LUMEVOQ®
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220719006077/en/
Figure 1. Evolution of BCVA In LUMEVOQ®-treated
DGAP-Adhoc: Drägerwerk AG & Co. KGaA: Preliminary figures for H1 2022: net sales and earnings significantly below prior year despite strong order entry – guidance confirmed due to expected business recovery in H2
DGAP-Adhoc: Drägerwerk AG & Co. KGaA: Preliminary figures for H1 2022: net sales and earnings significantly below prior year despite strong order entry – guidance confirmed due to expected business recovery in H2
Humana Foundation Announces Scholarship Awards
The Humana Foundation, the philanthropic arm of Humana Inc. (NYSE: HUM) for the past 40 years, announced 75 winners of college scholarships awarded through The Humana Foundation Scholarship